Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY Omicron XBB.1.5? COMIRNATY Omicron XBB.1.5 is a vaccine given to prevent coronavirus disease ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...